Akums Drugs and Pharmaceuticals Limited, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. The company operates as a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.
Akums Drugs & Pharmaceuticals are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
The company has achieved significant regulatory recognition, as some of its manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice, and the United States National Sanitation Foundation.
As of June 23, 2025, the market capitalization of Akums Drugs & Pharmaceuticals Ltd stood at ₹8,453.63 Crore. The company has a market cap of ₹9,105 Crore with revenue of ₹4,118 Crore and profit of ₹344 Crore. The company is almost debt-free, reflecting strong financial health.
FY 2025 Performance:
- Revenue: ₹4,118.16 Crore in the year ended March 2025, as against ₹4,178.18 Crore during the previous year ended March 2024.
- Net Profit: ₹338.18 Crore in the year ended March 2025, as against net loss of ₹4.04 Crore during the previous year ended March 2024.
Q4 FY25 Results:
- Revenue: ₹1,073.1 Crore in revenue and ₹149.61 Crore in net profit.
- Akums reported revenue of ₹1,073 Crore, reflecting a robust 12.4% year-on-year (YoY) growth.
Q1 FY25 Turnaround:
- Akums Drugs and Pharmaceuticals has reported a 5.08% year-on-year (Y-o-Y) increase in its revenue from operations for the first quarter of FY 2024-25, while the pharma major also scripted a turnaround and reported a net profit of ₹60.1 Crore during the quarter under review. In Q1 FY24, the firm had posted a loss of ₹188 Crore.
Profitability Indicators:
- Company has delivered good profit growth of 48.9% CAGR over the last 5 years.
- Stock P/E: 27.9, Book Value: ₹194, ROE: 17.2%, ROCE: 16.2%.
Debt Management:
- The debt-to-equity ratio improved to 0.25 times, and net debt decreased to ₹212.8 Crore.
Akums Healthcare's new injectable facility commenced commercial production on August 22, 2024. This facility has an annual capacity of 362 million units. The company's board of directors has approved a plan to establish two new production facilities in Jammu. These facilities, dedicated to pharmaceutical and nutraceutical products, will require a total investment of ₹265 Crore.
The Active Pharmaceutical Ingredients (API) segment also increased its revenue by 82.6% Y-o-Y. However, while the API business continues to struggle with EBITDA losses, management is optimistic about future profitability, particularly with a strong pipeline of international opportunities.
"With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a EUR 200 million contract." The contract involves manufacture and supply of products to be sold in European markets.
The company is strategically enhancing its operational capacity and focusing on R&D, increasing expenditure by 16% and launching 31 new products to drive long-term growth.
Promoter Holding: 75.3%, indicating strong promoter confidence in the business. Promoter holding in Akums Drugs & Pharmaceuticals Ltd has remained stable at 75.26% as of March 2025 (unchanged from August 2024).
The 52-week high of Akums Drugs & Pharmaceuticals Ltd share price is ₹1,175.90, while the 52-week low is ₹405.00. Over the past 6 months, the Akums Drugs & Pharmaceuticals share price has decreased by 6.23%, and in the last one year, it has decreased by 32.55%.
Akums Drugs and Pharmaceuticals demonstrated resilience in Q4 with a 9% year-on-year volume growth, despite facing significant challenges such as price erosion in APIs and muted demand in the trade generics segment. Improved working capital management and a cautious approach to M&A reflect a commitment to navigating current market volatility while positioning for sustainable growth.
Incorporated in 2004, Akums Drugs and Pharma is a pharmaceutical contract development and manufacturing organization (CDMO) which offers a comprehensive range of pharma products and services in India and overseas. It is engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs). The company's strong fundamentals, expanding manufacturing capacity, and strategic international partnerships position it well for future growth in the pharmaceutical sector.
